These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24970875)

  • 41. The Path Towards a Tailored Clinical Biosimilar Development.
    Schiestl M; Ranganna G; Watson K; Jung B; Roth K; Capsius B; Trieb M; Bias P; Maréchal-Jamil J
    BioDrugs; 2020 Jun; 34(3):297-306. PubMed ID: 32266678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
    Dingermann T; Scotte F
    Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
    Van de Wiele VL; Kesselheim AS; Sarpatwari A
    Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
    Lissy M; Ode M; Roth K
    Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study.
    He K; Chen H; Gwise T; Casak S; Lemery S; Keegan P; Pazdur R; Sridhara R
    Clin Cancer Res; 2016 Nov; 22(21):5167-5170. PubMed ID: 27582485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical safety of biosimilar recombinant human erythropoietins.
    Abraham I; MacDonald K
    Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
    McKinley L; Kelton JM; Popovian R
    Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilar biologic drugs: a new frontier in medical care.
    Geynisman DM; De Velasco G; Sewell KL; Jacobs I
    Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
    Rivera VM
    Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 'Global Reference' Comparator for Biosimilar Development.
    Webster CJ; Woollett GR
    BioDrugs; 2017 Aug; 31(4):279-286. PubMed ID: 28526943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.